SARS-CoV-2 Breakthrough Infections after introduction of 4 COVID-19 Vaccines, South Korea, 2021

We conducted a nationwide retrospective cohort study to estimate severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) breakthrough infection among recipients of 4 different vaccines in South Korea. Age-adjusted breakthrough infection rate per month was highest for Janssen (42.6/100,000 popul...

Descripción completa

Detalles Bibliográficos
Autores principales: Yi, Seonju, Choe, Young June, Kim, Jia, Kim, Yoo-Yeon, Kim, Ryu Kyung, Jang, Eun Jung, Lim, Do Sang, Byeon, Hye Ryeon, Lee, Sangwon, Park, Eonjoo, Kim, Seung-Jin, Park, Young-Joon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Centers for Disease Control and Prevention 2022
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8888240/
https://www.ncbi.nlm.nih.gov/pubmed/35202529
http://dx.doi.org/10.3201/eid2803.212210
_version_ 1784661096655749120
author Yi, Seonju
Choe, Young June
Kim, Jia
Kim, Yoo-Yeon
Kim, Ryu Kyung
Jang, Eun Jung
Lim, Do Sang
Byeon, Hye Ryeon
Lee, Sangwon
Park, Eonjoo
Kim, Seung-Jin
Park, Young-Joon
author_facet Yi, Seonju
Choe, Young June
Kim, Jia
Kim, Yoo-Yeon
Kim, Ryu Kyung
Jang, Eun Jung
Lim, Do Sang
Byeon, Hye Ryeon
Lee, Sangwon
Park, Eonjoo
Kim, Seung-Jin
Park, Young-Joon
author_sort Yi, Seonju
collection PubMed
description We conducted a nationwide retrospective cohort study to estimate severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) breakthrough infection among recipients of 4 different vaccines in South Korea. Age-adjusted breakthrough infection rate per month was highest for Janssen (42.6/100,000 population), followed by AstraZeneca (21.7/100,000 population), Pfizer-BioNTech (8.5/100,000 population), and Moderna (1.8/100,000 population).
format Online
Article
Text
id pubmed-8888240
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Centers for Disease Control and Prevention
record_format MEDLINE/PubMed
spelling pubmed-88882402022-03-02 SARS-CoV-2 Breakthrough Infections after introduction of 4 COVID-19 Vaccines, South Korea, 2021 Yi, Seonju Choe, Young June Kim, Jia Kim, Yoo-Yeon Kim, Ryu Kyung Jang, Eun Jung Lim, Do Sang Byeon, Hye Ryeon Lee, Sangwon Park, Eonjoo Kim, Seung-Jin Park, Young-Joon Emerg Infect Dis Research Letter We conducted a nationwide retrospective cohort study to estimate severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) breakthrough infection among recipients of 4 different vaccines in South Korea. Age-adjusted breakthrough infection rate per month was highest for Janssen (42.6/100,000 population), followed by AstraZeneca (21.7/100,000 population), Pfizer-BioNTech (8.5/100,000 population), and Moderna (1.8/100,000 population). Centers for Disease Control and Prevention 2022-03 /pmc/articles/PMC8888240/ /pubmed/35202529 http://dx.doi.org/10.3201/eid2803.212210 Text en https://creativecommons.org/licenses/by/4.0/Emerging Infectious Diseases is a publication of the U.S. Government. This publication is in the public domain and is therefore without copyright. All text from this work may be reprinted freely. Use of these materials should be properly cited.
spellingShingle Research Letter
Yi, Seonju
Choe, Young June
Kim, Jia
Kim, Yoo-Yeon
Kim, Ryu Kyung
Jang, Eun Jung
Lim, Do Sang
Byeon, Hye Ryeon
Lee, Sangwon
Park, Eonjoo
Kim, Seung-Jin
Park, Young-Joon
SARS-CoV-2 Breakthrough Infections after introduction of 4 COVID-19 Vaccines, South Korea, 2021
title SARS-CoV-2 Breakthrough Infections after introduction of 4 COVID-19 Vaccines, South Korea, 2021
title_full SARS-CoV-2 Breakthrough Infections after introduction of 4 COVID-19 Vaccines, South Korea, 2021
title_fullStr SARS-CoV-2 Breakthrough Infections after introduction of 4 COVID-19 Vaccines, South Korea, 2021
title_full_unstemmed SARS-CoV-2 Breakthrough Infections after introduction of 4 COVID-19 Vaccines, South Korea, 2021
title_short SARS-CoV-2 Breakthrough Infections after introduction of 4 COVID-19 Vaccines, South Korea, 2021
title_sort sars-cov-2 breakthrough infections after introduction of 4 covid-19 vaccines, south korea, 2021
topic Research Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8888240/
https://www.ncbi.nlm.nih.gov/pubmed/35202529
http://dx.doi.org/10.3201/eid2803.212210
work_keys_str_mv AT yiseonju sarscov2breakthroughinfectionsafterintroductionof4covid19vaccinessouthkorea2021
AT choeyoungjune sarscov2breakthroughinfectionsafterintroductionof4covid19vaccinessouthkorea2021
AT kimjia sarscov2breakthroughinfectionsafterintroductionof4covid19vaccinessouthkorea2021
AT kimyooyeon sarscov2breakthroughinfectionsafterintroductionof4covid19vaccinessouthkorea2021
AT kimryukyung sarscov2breakthroughinfectionsafterintroductionof4covid19vaccinessouthkorea2021
AT jangeunjung sarscov2breakthroughinfectionsafterintroductionof4covid19vaccinessouthkorea2021
AT limdosang sarscov2breakthroughinfectionsafterintroductionof4covid19vaccinessouthkorea2021
AT byeonhyeryeon sarscov2breakthroughinfectionsafterintroductionof4covid19vaccinessouthkorea2021
AT leesangwon sarscov2breakthroughinfectionsafterintroductionof4covid19vaccinessouthkorea2021
AT parkeonjoo sarscov2breakthroughinfectionsafterintroductionof4covid19vaccinessouthkorea2021
AT kimseungjin sarscov2breakthroughinfectionsafterintroductionof4covid19vaccinessouthkorea2021
AT parkyoungjoon sarscov2breakthroughinfectionsafterintroductionof4covid19vaccinessouthkorea2021

Ejemplares similares